[Form 4] Larimar Therapeutics, Inc. Insider Trading Activity
Larimar Therapeutics (LRMR) reported an insider trading activity in a Form 4 filing. The report details a stock option grant to an entity associated with Deerfield Management, covering 55,150 common shares with an exercise price of $3.33 and an expiration date of May 19, 2036. The options were granted to Jonathan S. Leff, a director of Larimar, and are held for the benefit of Deerfield Management Company, L.P. The options will vest upon Leff's continued board service, either on May 19, 2027, or the date of Larimar's next annual stockholder meeting.
Larimar Therapeutics (LRMR) entity tied to director receives 55,150 stock options
Larimar Therapeutics (LRMR) reported that an entity associated with director Jonathan S. Leff was granted 55,150 stock options with an exercise price of $3.33 per share, expiring on May 19, 2036. Leff, a partner at Deerfield Management Company, L.P., disclaims personal beneficial ownership, holding the options for Deerfield, and they vest subject to his continued service on the board. This transaction represents a neutral filing impact and sentiment, detailing the specifics of the compensatory grant and its terms.
Larimar Therapeutics (LRMR) awards 55,150 stock options to director
Larimar Therapeutics director Jeffrey W. Sherman was granted 55,150 stock options with an exercise price of $3.33 per share, expiring on May 19, 2036. This compensation-related award vests on the earlier of May 19, 2027, or the company's next annual stockholder meeting, contingent on his continued board service. This transaction is categorized as an award, not an open-market trade.
Larimar Therapeutics (LRMR) director receives 55,150 stock options grant
Larimar Therapeutics director Joseph Truitt was granted 55,150 stock options with an exercise price of $3.33 per share, expiring on May 19, 2036. These options vest on the earlier of May 19, 2027, or the date of the next annual meeting, contingent on his continued service on the Board of Directors. Following this grant, Truitt directly holds 55,150 stock options.
Larimar Therapeutics (LRMR) director awarded 55,150 stock options at $3.33 strike
Larimar Therapeutics director Frank E. Thomas was granted 55,150 stock options as equity compensation, with an exercise price of $3.33 per share. These options vest on the earlier of May 19, 2027, or the date of the next annual stockholder meeting, contingent on his continued service on the board. This transaction is considered a routine, service-based incentive rather than an open-market trade.
Larimar Therapeutics (LRMR) director gets 55,150 stock options at $3.33 strike
Larimar Therapeutics director Thomas Edward Hamilton was granted 55,150 stock options with an exercise price of $3.33 per share, expiring on May 19, 2036. These options vest on the earlier of May 19, 2027, or the company's next annual stockholder meeting, contingent on his continued service on the board. This transaction is a compensation-related award and not an open-market purchase or sale of common stock.
Larimar Therapeutics stockholders approve board elections and share increase
Larimar Therapeutics (NASDAQ:LRMR) stockholders approved the election of three Class III directors, advisory executive compensation, and ratification of PricewaterhouseCoopers LLP as the accounting firm. Crucially, they also approved an amendment to increase the authorized common stock from 115 million to 215 million shares. The decisions follow a period of significant company activity, including a successful equity offering and Breakthrough Therapy designation for its drug candidate, nomlabofusp.
Larimar Therapeutics (NASDAQ: LRMR) holders back big authorized share increase
Larimar Therapeutics stockholders approved a significant increase in authorized common shares from 115 million to 215 million at their 2026 annual meeting. This move expands the company's capacity for future equity-related actions, although it does not immediately issue new shares. Shareholders also re-elected Class III directors, approved executive compensation, and ratified PricewaterhouseCoopers LLP as the independent auditor for 2026.
Larimar Therapeutics (Nasdaq:LRMR) - Stock Analysis
Larimar Therapeutics (Nasdaq:LRMR) is a clinical-stage biotechnology company focused on developing treatments for rare diseases, particularly Friedreich's ataxia (FA) with its lead candidate nomlabofusp. The stock is currently trading at US$3.57, well below an analyst price target of US$15.88, indicating it is significantly undervalued. Recent news includes FDA Breakthrough Therapy Designation for nomlabofusp and a planned Biologics License Application (BLA) submission for June 2026, alongside several equity offerings and positive long-term study data.
Larimar Therapeutics, Inc. Stock 12‑Month Price Target Cut to $15.88, Implies 287% Upside
Larimar Therapeutics, Inc. (LRMR) has seen its average 12-month price target adjusted from $16 to $15.88 by analysts, with a range spanning $7 to $26. This updated target indicates a potential upside of approximately 287% based on its recent closing price. The consensus analyst rating for LRMR remains a "Buy" from all nine covering analysts.
[10-Q] Larimar Therapeutics, Inc. Quarterly Earnings Report
Larimar Therapeutics, Inc. reported a net loss of $29.6 million for the first quarter ended March 31, 2026, consistent with the previous year, as it continues to heavily invest in developing nomlabofusp for Friedreich's ataxia. The company's cash, cash equivalents, and marketable securities increased to $200.4 million after a February equity offering, which is expected to fund operations for at least twelve months. Nomlabofusp received FDA Breakthrough Therapy Designation, and Larimar plans to initiate a rolling Biologics License Application submission starting in June 2026, aiming for a potential U.S. launch in the first half of 2027 if approved.
Blue Owl (NASDAQ: LRMR) discloses 9.99% position totaling 10.74M shares
Blue Owl Capital Holdings LP has reported a 9.99% beneficial ownership in Larimar Therapeutics, Inc. (NASDAQ: LRMR), amounting to 10,739,492 shares. This stake includes common stock, call options, and convertible Series A preferred stock. The filing, a Schedule 13G/A, indicates that a conversion blocker limits the reported beneficial ownership to 9.99%, despite the underlying Series A preferred stock having the potential to convert into a larger number of common shares.
Larimar Therapeutics 1Q Research and Development Expenses $25.0M >LRMR
Larimar Therapeutics reported its first-quarter research and development expenses were $25.0 million. This figure provides insight into the company's investment in its drug development pipeline during the specified period. Further financial details would be needed to assess the full context of these expenses.
LRMR: Nomlabofusp shows strong efficacy and safety in FA, targeting 2027 U.S. launch
Nomlabofusp, a novel therapy by LRMR for Friedreich's ataxia, has demonstrated strong efficacy and a favorable safety profile in open-label studies by increasing frataxin levels and improving clinical outcomes. The company plans for a rolling BLA submission in 2026, aiming for a U.S. launch in 2027. This information is based on a recent slides release from Larimar Therapeutics.
Larimar Therapeutics (LRMR) boosts cash, eyes 2027 launch for FA therapy
Larimar Therapeutics reported its first quarter 2026 financial results, including a net loss of $29.6 million, and provided updates on its Friedreich’s ataxia (FA) therapy, nomlabofusp. The company holds $200.4 million in cash, cash equivalents, and marketable securities, extending its projected cash runway into Q2 2027. Larimar plans a rolling Biologics License Application (BLA) submission for nomlabofusp in June 2026, targeting a potential U.S. launch in the first half of 2027, given regulatory approval.
Rare ataxia drug nomlabofusp heads for FDA filing and possible 2027 launch
Larimar Therapeutics (Nasdaq: LRMR) announced Q1 2026 results and significant progress for its Friedreich's ataxia drug, nomlabofusp. The company plans to initiate a rolling BLA submission for accelerated approval in June 2026, targeting a potential launch in the first half of 2027 if approved. Larimar reported $200.4 million in cash and securities, providing a cash runway into Q2 2027, despite a Q1 2026 net loss of $29.6 million.
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
Larimar Therapeutics announced its first quarter 2026 financial and business results, revealing plans to initiate a rolling Biologics License Application (BLA) submission for nomlabofusp in June 2026, seeking accelerated approval for Friedreich’s ataxia. The company reported $200.4 million in cash, cash equivalents, and marketable securities, projecting a cash runway into Q2 2027. Key upcoming milestones include reporting topline open-label study data and initiating a global confirmatory Phase 3 study in mid-2026, targeting a potential launch in the first half of 2027 if approved.
Larimar: Q1 Earnings Snapshot
Larimar Therapeutics, Inc. (LRMR) reported a first-quarter loss of $29.6 million, or 31 cents per share. This financial performance exceeded Wall Street expectations, as analysts had predicted a larger loss of 53 cents per share. The results were compiled from data by Zacks Investment Research and reported by Automated Insights.
Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study
Larimar Therapeutics' stock is declining in pre-market trading due to a high rate of anaphylaxis observed in a Phase 2 clinical trial for its drug, CTI-1601. The trial, targeting Friedreich's ataxia, showed a 6.7% anaphylaxis rate, leading to further investigation and a safety protocol adjustment. Despite the setback, the company plans to provide an update in the second half of 2024.
Larimar Data Support Surrogate Endpoint for Nomlabofusp Approval Path
Larimar Therapeutics has published data supporting the use of skin-based frataxin measurements as a surrogate endpoint for its experimental therapy, nomlabofusp, for Friedreich's ataxia. This could accelerate the U.S. approval pathway as the findings show frataxin levels in accessible tissues correlate with those in clinically relevant organs. The company plans to submit a Biologics License Application in June 2026 under the accelerated approval pathway.
Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and Larimar Therapeutics (LRMR)
Analysts from Wells Fargo and LifeSci Capital have issued bullish ratings for healthcare companies Stryker (SYK) and Larimar Therapeutics (LRMR), respectively. Stryker received a Buy rating with a $418.00 price target from Wells Fargo's Larry Biegelsen, while Larimar Therapeutics was reiterated as a Buy with a $25.00 price target by LifeSci Capital's Francois Brisebois. Both companies show strong analyst consensus, with Stryker having a 31.6% implied upside and Larimar Therapeutics having a $13.90 average target.
Larimar Therapeutics, Inc. $LRMR Shares Acquired by AIGH Capital Management LLC
AIGH Capital Management LLC significantly increased its stake in Larimar Therapeutics (NASDAQ:LRMR) by 100% in Q4, acquiring an additional 1,000,000 shares, making LRMR its 17th-largest holding. Additionally, Director James E. Flynn bought 5,000,000 shares for $25 million, boosting his ownership to 10,622,957 shares. Despite a recent EPS miss, analysts maintain an average target price of $16.50, suggesting substantial upside.
Millennium Management (LRMR) reports 3.5% ownership; 3,625,278 shares
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly reported a beneficial ownership of 3,625,278 shares, representing 3.5% of Larimar Therapeutics (LRMR) common stock. This update is filed as an Amendment No. 2 to a Schedule 13G/A, indicating a passive investment intent. The shares are held by entities under the voting and investment discretion of the reporting persons, as stated in a Joint Filing Agreement dated April 29, 2026.
Larimar Therapeutics Publishes Cross-Species Findings
Larimar Therapeutics announced the publication of cross-species findings supporting the use of skin as a surrogate for frataxin measurement in Friedreich’s ataxia (FA) treatment. The study, published in Clinical and Translational Science, demonstrates that nomlabofusp treatment increases frataxin levels in relevant tissues, correlating with levels in accessible peripheral tissues like skin and buccal cells. These findings reinforce Larimar’s accelerated approval pathway strategy and aim to support their Biologics License Application (BLA) submission for nomlabofusp as a potential disease-modifying therapy for FA.
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Brokerages
Ten brokerages have given Larimar Therapeutics (NASDAQ:LRMR) a consensus "Buy" rating, with an average one-year price target of $16.50. The company, focused on developing treatments for rare diseases like Friedreich's ataxia with its lead candidate CTI-1601, recently saw a significant insider purchase where Director James E. Flynn acquired 5 million shares for $25 million. Analysts anticipate negative EPS for the current fiscal year, having recently missed quarterly estimates.
Larimar Therapeutics stock dips after pricing $100M share offering
Larimar Therapeutics' stock declined following the announcement of a $100 million public offering of its common stock. The company plans to use the net proceeds from this offering for clinical development activities, working capital, and general corporate purposes. This financial move suggests a strategy to fuel its ongoing research and operational needs.
[ARS] Larimar Therapeutics, Inc. SEC Filing
This article announces an ARS SEC filing by Larimar Therapeutics, Inc. (LRMR) on April 20, 2026. The filing has a low impact and neutral sentiment, and the article provides a link to the full PDF document on SEC EDGAR. It also includes recent news and SEC filings related to Larimar Therapeutics, Inc.
Larimar Therapeutics (LRMR) to Release Earnings on Wednesday
Larimar Therapeutics (LRMR) is set to release its Q1 2026 earnings before market open on April 29th, with analysts projecting a loss of ($0.51) per share. The company previously missed estimates, reporting ($0.73) EPS against a ($0.43) consensus, and expects a ($2) EPS for both the current and next fiscal years. Despite this, the stock has an average "Buy" rating with a target of $16.50, and a director recently made a significant insider purchase of 5,000,000 shares.
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development
Larimar Therapeutics announced its first quarter 2025 financial results. The company provided an update on the progress of its lead drug candidate, nomlabofusp, for the treatment of Friedreich's Ataxia, highlighting its ongoing clinical development.
LRMR Forecast, Price Target & Analyst Ratings | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR)
LARIMAR THERAPEUTICS INC (LRMR) has a consensus price target of $17.03 from 17 Wall Street analysts, implying a 260.89% upside from its current price of $4.72. The stock has a ChartMill Buy Consensus Rating of 89.41%, indicating strong analyst confidence. LRMR is expected to report Q1 2026 earnings on May 7, 2026, with an estimated EPS of -$0.57.
LRMR stock on the move: What sparked the 55% jump in the past month?
The article discusses the significant 55% surge in LRMR stock over the past month. It aims to investigate the underlying reasons or catalysts that have driven this substantial price movement for the company.
Analysts Set Larimar Therapeutics Price Target at $16.50
Analysts have assigned Larimar Therapeutics, Inc. (NASDAQ:LRMR) an average price target of $16.50, with a majority giving the stock "buy" or "strong buy" ratings. This optimism stems from the biotech company's promising rare disease pipeline, particularly its lead drug candidate CTI-1601 for Friedreich's ataxia. Insider stock purchases and recent earnings reports further underscore the positive sentiment around the company's future growth potential.
LRMR stock on the move: What sparked the 55% jump in the past month?
The article "LRMR stock on the move: What sparked the 55% jump in the past month?" is currently empty, but its title indicates it would discuss the reasons behind a significant 55% surge in LRMR stock over the past month.
LRMR PE Ratio & Valuation, Is LRMR Overvalued
Larimar Therapeutics Inc (LRMR) is currently in the "Fair zone" according to its forward PS ratio of 7.95, which is compared to a five-year average of -3.46. While its current Price-to-Book (P/B) ratio of 6.37 is significantly higher than its 3-year and 5-year averages, its Forward Free Cash Flow (FCF) yield is -22.77%. The article also notes that LRMR's P/S ratio of 7.95 is significantly above the industry average, suggesting that its premium based on growth may be unsustainable.
Q1 Earnings Estimate for LRMR Issued By Lifesci Capital
Lifesci Capital has issued Q1 2026 EPS estimates for Larimar Therapeutics (NASDAQ:LRMR) at ($0.66) per share, maintaining a "Strong-Buy" rating. The consensus rating for LRMR is a "Buy" with an average price target of $16.50. The article also highlights recent insider buying activity and institutional investor holdings.
LRMR SEC Filings - Larimar Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Larimar Therapeutics, Inc. (LRMR) SEC filings, including 10-K, 10-Q, and 8-K reports, detailing the company's clinical progress, financial condition, and key events. Larimar is a clinical-stage biotechnology company focused on rare diseases, with its lead compound, nomlabofusp, in development for Friedreich's ataxia. The platform also offers AI-powered summaries, impact scoring, and sentiment analysis for these regulatory documents, alongside real-time updates and insider transaction data.
Wedbush raises its price target on Larimar Therapeutics (LRMR) to $13
Wedbush has increased its price target for Larimar Therapeutics (LRMR) to $13. This indicates a positive outlook from the analyst firm regarding the company's future stock performance.
Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13
Wedbush has increased its price target for Larimar Therapeutics (LRMR) to $13 from $12, maintaining an Outperform rating. This decision follows Larimar's Q4 update, which met expectations as the company prepares to submit its nomlabofusp regulatory application in June 2026. Larimar reported Q4 EPS of (73c) and a strong cash position, supporting its operations into Q2 2027.
Larimar Therapeutics (NASDAQ:LRMR) Stock Rating Upgraded by Truist Financial
Truist Financial upgraded Larimar Therapeutics (NASDAQ:LRMR) to a "strong-buy" rating, contributing to an overall analyst consensus of "Buy" with a $16.50 price target. This comes after Director James E. Flynn made a significant insider purchase of 5,000,000 shares for $25,000,000, increasing his stake to over 10 million shares. Despite recent earnings missing expectations, the company is advancing its lead product candidate, CTI-1601, for Friedreich's ataxia in Phase 2 clinical trials.
Larimar Reports Results, Advances Nomlabofusp Toward FDA Filing
Larimar Therapeutics, Inc. reported its Q4 and full-year 2025 financial results and provided updates on its lead candidate, nomlabofusp, for Friedreich’s ataxia. The company plans an FDA filing for accelerated approval in June 2026 and expects its cash runway to extend into Q2 2027 following a recent public offering. The FDA has granted Breakthrough Therapy Designation for nomlabofusp and agreed on key aspects for the planned Biologics License Application and Phase 3 study.
FDA grants Breakthrough status to rare disease drug as June filing nears
Larimar Therapeutics (NASDAQ: LRMR) announced that the FDA granted Breakthrough Therapy Designation to nomlabofusp for Friedreich’s ataxia, with a Biologics License Application (BLA) submission seeking accelerated approval planned for June 2026. The company also reported Q4 and full-year 2025 financial results, including a net loss of $165.7 million for the year, and strengthened its balance sheet with a $115 million public offering, extending its cash runway into Q2 2027. Investors are advised to watch for upcoming open-label data and Phase 3 initiation as key indicators of execution risk.
Larimar Therapeutics (LRMR) Expected to Announce Earnings on Monday
Larimar Therapeutics (LRMR) is set to announce its Q4 2025 earnings before market open on Monday, March 30th, with analysts expecting a loss of ($0.41) per share. Despite missing previous estimates and projected negative EPS for the coming fiscal years, the stock maintains a consensus "Buy" rating and a mean price target of $16.43. Noteworthy insider activity includes a significant purchase by Director James E. Flynn, increasing his stake by 88.9%.
Larimar Therapeutics (NASDAQ:LRMR) Stock Price Up 8.2% After Analyst Upgrade
Larimar Therapeutics' (NASDAQ:LRMR) stock price rose by 8.2% after Wedbush increased its price target to $13.00. The company also saw significant insider buying, with Director James E. Flynn purchasing 5,000,000 shares worth $25 million, and strong institutional accumulation of its stock. Analysts currently hold a consensus "Buy" rating for LRMR with an average price target of $16.43.
Wedbush Increases Larimar Therapeutics (NASDAQ:LRMR) Price Target to $13.00
Wedbush has increased its price target for Larimar Therapeutics (NASDAQ:LRMR) to $13.00 from $12.00, maintaining an "outperform" rating and implying a potential upside of 190.83%. This adjustment aligns with a general "Buy" consensus from other analysts, with an average price target of $16.43. The report also highlights a significant insider purchase by Director James E. Flynn, who acquired 5,000,000 shares for $25,000,000, substantially increasing his stake in the company.
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Larimar Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting significant progress for its lead compound, nomlabofusp, in treating Friedreich's ataxia (FA). The company received Breakthrough Therapy Designation from the FDA and is on track for a Biologics License Application (BLA) submission in June 2026, targeting an accelerated approval and a mid-2027 U.S. launch. Larimar also completed a successful $115 million public offering, extending its cash runway into the second quarter of 2027.
Larimar Therapeutics, Inc. has established a clear regulatory approval and commercialization timeline for its core candidate product.
Larimar Therapeutics, Inc. has outlined a timeline for its core candidate product, intending to submit a Biologics License Application (BLA) to the FDA in June 2026. The company anticipates an official launch in the U.S. market in the first half of 2027, assuming a successful approval process. This plan provides a clear commercialization path for their therapeutic offering.
Larimar Therapeutics, Inc. has established a clear regulatory approval and commercialization timeline for its core candidate product.
Larimar Therapeutics, Inc. has set a clear timeline for its core product, planning to submit a Biologics License Application (BLA) to the FDA in June 2026. If approved without issues, the company expects to launch the therapy in the U.S. market in the first half of 2027.
Larimar (NASDAQ: LRMR) secures FDA Breakthrough status and funds runway to 2027
Larimar Therapeutics (NASDAQ: LRMR) announced a wider net loss of $165.7 million in 2025 but achieved FDA Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia. The company has secured $244.5 million in pro forma liquidity, extending its cash runway into Q2 2027, and plans a Biologics License Application (BLA) submission for nomlabofusp in June 2026, targeting a U.S. launch in early 2027 if approved. Despite increased R&D expenses driven by manufacturing and clinical costs, regulatory alignment with the FDA on using frataxin as a surrogate endpoint underpins a clear development path for its lead asset.
Larimar Therapeutics Q4 net loss widens on higher R&D costs
Larimar Therapeutics reported a wider net loss in the fourth quarter due to increased research and development costs. The article, a brief report from Reuters via Refinitiv, indicates that the Q4 earnings were negatively impacted by these higher expenses.
Larimar: Q4 Earnings Snapshot
Larimar Therapeutics, Inc. (LRMR) reported a fourth-quarter loss of $62.5 million, or 73 cents per share, which missed Wall Street expectations of 44 cents per share. For the entire year, the company had a loss of $165.7 million, or $2.27 per share. This financial data was generated by Automated Insights using information from Zacks Investment Research.
